(Total Views: 559)
Posted On: 05/16/2024 1:39:46 PM
Post# of 148870
Good to see some progress on trial planning and a nice letter from Dr. Jay.
It seems like this CRC trial is a new strategy (before was just talking about the HIV inflammation exploratory trial).
I'm wondering if we can speculate on details on this trial, and why they chose this cancer indication versus others.
Some other CCR5 small molecule inhibitor (maraviroc, vicriviroc) CRC trials in combo with anti-PD1 pembrolizumab immunotherapy showed poor results, including one just published a few days ago, and another from 2022:
https://www.clinical-colorectal-cancer.com/ar...1/abstract
https://www.sciencedirect.com/science/article...4922001617
Only 5% response rate. Can we expect leronlimab to improve on this?
I wonder if they would run as a monotherapy, add-on, or what in refractory/recurrent CRC.
If we are thinking other cancers, brain cancer / GBM, triple negative breast cancer (for which we already have some data), or even prostate cancer would seem like good bets.
I think getting a partner like Astellas to run a trial using leronlimab as a sensitizer for enzalutamide in prostate cancer would look like a good gamble:
https://www.cell.com/iscience/fulltext/S2589-0042(24)00896-4
Hard to know which cancer indication to go after with leronlimab. I guess CRC as good as any of them.
It seems like this CRC trial is a new strategy (before was just talking about the HIV inflammation exploratory trial).
Quote:
a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer
I'm wondering if we can speculate on details on this trial, and why they chose this cancer indication versus others.
Some other CCR5 small molecule inhibitor (maraviroc, vicriviroc) CRC trials in combo with anti-PD1 pembrolizumab immunotherapy showed poor results, including one just published a few days ago, and another from 2022:
https://www.clinical-colorectal-cancer.com/ar...1/abstract
https://www.sciencedirect.com/science/article...4922001617
Only 5% response rate. Can we expect leronlimab to improve on this?
I wonder if they would run as a monotherapy, add-on, or what in refractory/recurrent CRC.
If we are thinking other cancers, brain cancer / GBM, triple negative breast cancer (for which we already have some data), or even prostate cancer would seem like good bets.
I think getting a partner like Astellas to run a trial using leronlimab as a sensitizer for enzalutamide in prostate cancer would look like a good gamble:
https://www.cell.com/iscience/fulltext/S2589-0042(24)00896-4
Hard to know which cancer indication to go after with leronlimab. I guess CRC as good as any of them.
(4)
(1)Scroll down for more posts ▼
